After completion of my board certification in Medical Oncology and Medical Genetics at Tel Aviv Medical Center, I joined Breast Cancer Institute at the Sheba Medical Center at Tel Hashomer in 2017, where I worked as a medical oncologist and a clinical cancer geneticist. At 3/2021, I was appointed as a director of the Oncogenetics Unit at the Institute of Genetics. I am a member of the Israeli Consortium of Hereditary Breast Cancer since 2017, and have several national and international collaborations. My area of clinical research interest is hereditary cancer predisposition syndromes, particularly modifier risk factors in breast cancer.
Education:
2011-2014, Residency – Genetic Institute, Tel Aviv Sourasky Medical Center,
Tel Aviv, Israel. Supervision: Prof. Avi Orr (Urtregger)
2005-2011, Residency - Oncology Department, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Supervision: Prof. Moshe Inbar
2004-2005, Internship in Medicine, Wolfson Hospital, Holon, Israel
1997-2004, M.D., Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel
Employment History Experience:
2021 to present, Head, Susanne Levy Gertner Oncogenetics Unit, The Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Israel
2017 to present, Senior physician, Breast Cancer Unit, Oncology Institute, Sheba Medical Center, Tel Hashomer, Israel
2014-2017, Senior physician, Oncology Department and Genetics Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Academic Appointments:
2021 to present, Senior Lecturer, Sackler Faculty of Medicine, Tel Aviv University
2016 to 2021, Clinical Instructor, Faculty of Medicine, Tel Aviv University
Membership in Professional/ Scientific Societies:
The Israeli Society for Clinical Oncology and Radiation Therapy
Israeli Medical Association (IMA)
The Israeli Society of Medical Genetics
European Society for Medical Oncology
Awards, Citations, Honors, Competitive Fellowships:
2021, Principal investigator, Genomic determinants of age at diagnosis of breast cancer in BRCA1 mutation carriers, Israel Cancer Association (75,000 NIS)
2019, Co-investigator, PI Dr. Maya Dadiani, Subtype switch between primary and recurrent breast cancer: the underlying molecular mechanism and therapeutic implications, Israel Cancer Association (45,000 NIS)
Publications:
Here is a link to the list of publications for Dr. Bernstein Molho in PubMed
